[Clinical management of premature rupture of fetal membranes to the 35th week].
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001623:Betamethasone / Q000627:therapeutic use; D002821:Chorioamnionitis / Q000517:prevention & control; D003131:Combined Modality Therapy; D005260:Female; D005322:Premature Rupture of Fetal Membranes / Q000628:therapy*; D005325:Fetal Organ Maturity / Q000187:drug effects; D005865:Gestational Age; D006801:Humans; D007231:Infant, Newborn; D007752:Obstetric Labor, Premature / Q000517:prevention & control; D011247:Pregnancy; D012127:Respiratory Distress Syndrome, Newborn / Q000517:prevention & control
D000900:Anti-Bacterial Agents; D001623:Betamethasone
Klinisches Management des vorzeitigen Blasensprungs bis zur 35. Woche.